Recursion Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Recursion reported updated phase 2 Tupelo data for REC 481 in FAP: after 12 weeks of treatment, 87% of evaluable patients had reduced total polyp burden, and about one in three had a reduction of at least 65%.
- About 85% of evaluable patients remained below baseline total polyp burden after 12 weeks off treatment; reductions were also reported in the upper and lower GI tracts and in larger, higher-risk polyps.
- At 4 milligrams qd, 21 of 26 safety-evaluable patients had grade 1 or 2 treatment-related side effects; four had grade 3 events, no grade 4 or 5 treatment-related AEs were reported, and there were no additional discontinuations in the update.
- REC 1245 showed three partial responses in dose escalation: two confirmed responses in endometrial cancer and one unconfirmed response in hepatocellular carcinoma. Disease control at eight weeks was 91.7%, or 11 of 12 patients, at doses of 45 milligrams and above.
- Recursion selected 45 milligrams once daily for REC 1245 expansion; at that dose, there were no dose-limiting toxicities or serious treatment-related adverse events.
- Sanofi optioned a development candidate, a potential first-in-class oral small molecule designed to inhibit two targets, triggering a $10 million payment and bringing total upfront and milestone payments from Sanofi to $144 million.
- Genentech optioned the first neuroscience target from Recursion's proprietary maps, and small molecule discovery is underway; Roche and Recursion also reported work identifying a mechanism for acting on a cancer pathway long considered undruggable.
- Recursion completed an oversubscribed $200 million follow-on offering in October; pro forma cash and equivalents were $749 million as of September 30th, excluding the recent $10 million Sanofi milestone, and the company said its cash runway extends into 2029.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone, and thank you for joining Recursion's third quarter earnings call. We're hosting earnings live from the CGA-IGC Annual Meeting in Denver. Today, we'll share the new FAP data that was presented yesterday at CGA by Dr. Lisa Boardman, along with updates in our oncology program, REC-1245, and progress across our partnerships. Before we get into the data, I want to start with the philosophy behind what we're building. To pioneer a new blueprint for making medicines with AI, we believe you have to tie together three core capabilities in one engine: uncover novel biology, design differentiated molecules against challenging targets, and generate clinical evidence that matters for patients. That is what we're building at Recursion. The higher bar we set for ourselves is repeatability. Not one target, not one molecule, or one clinical result, but the ability to do this across programs again and again.
Let me show you the progress we're making. Let me start with what we're seeing in patients. We now have positive clinical data from two first-in-class programs. With REC-4881 in FAP, we saw deep reductions in polyp burden that persisted off treatment. Now we're also seeing activity across the GI and reduction of larger high-risk polyps. We'll walk you through some of that data today. With REC-1245, we've seen partial responses in heavily pretreated cancer patients, two confirmed and one unconfirmed PR. In that program, our AI platform guided all three decisions, from biological insight on which target to pursue, how to design the molecule, and which patients to study. If you take a step back to molecule design, Sanofi recently optioned a potential first-in-class oral I&I candidate. The chemistry challenge behind that was to design a single molecule that could inhibit two targets.
When we talk about novel causal biology, we use the data that we have generated to build proprietary maps of biology and identify targets that may be driving disease. Genentech has now advanced the first neuroscience target from those maps, and we're working together on small molecules against it. That's the repeatability we're starting to see, the same engine uncovering novel targets, producing new molecules, and generating evidence in patients. Behind the progress you just saw is one AI platform that connects biology, chemistry, and the clinic. We draw on more than 50 petabytes of proprietary data to make decisions about which targets to pursue, which molecules to design, and which patients to study. What makes our approach repeatable is how we learn.
We generate our own proprietary data, which builds our models, which then in turn guide the experiments we run, and what we learn in the lab and in the clinic now then feeds back into those models. So an insight from one program can shape what we test in the next. Let's start by looking a little bit more into the data from REC-4881 and 1245. Here, we're sharing a summary of the early clinical data from these programs. First, with REC-4881 in FAP, remember there's no approved drug treatment. We previously have shown deep, durable reductions in total polyp burden. What's new is first, we have updated this data to expand the adult population to 18 and over, and we continue to see these substantial reductions.
In addition to that, we're seeing significant reduction throughout the GI tract, including the upper GI, which is a huge area of unmet need. In addition to that, we're also seeing reductions in the number of larger, higher-risk polyps. The safety profile remains favorable, with mostly grade 1 or 2 adverse events and no additional discontinuations in this update. With REC-1245, as I mentioned, we are seeing early single-agent activity in heavily pretreated patients with solid tumors. Vicki will walk you through the partial responses in the exploratory expansion cohort we have opened. Again, to say, look, the biological insight behind each program came from our platform. With REC-1245, you can see how our use of the platform continues to evolve.
We're not just using it for biological insight on the target, but we're also using it to design the molecule, and now it's helping us decide which patient populations to study. You can see that same evolution in our partners as well. Genentech optioned the first unexplored neuroscience target from our proprietary maps. Sanofi optioned the first development candidate from our collaboration, a potential first-in-class oral small molecule for I&I. Each of these programs have over $300 million in milestones with high single to double-digit royalties. In total, in our partnerships, we have now achieved more than $535 million in cash inflows from our partners. What gives me confidence in the repeatability of this work is that in roughly two years, we have earned more than $100 million across nine milestones tied to the progress in these partnerships.
I'd love to remind everybody that, look, underpinning all of this progress is how we use our data and the fact that we have one single engine. One of the biggest rate-limiting steps in science is the access to high-quality relevant data, and we have built a scientific data factory designed to generate this at scale. Our AI models draw on more than 50 petabytes of proprietary biological data to identify these novel potential causal targets. We then test those predictions experimentally and feed the results back into the models to guide the next experiment. That closed loop is how proprietary data can become a map. A map can then surface a new target, and that target can ultimately become a new program that either we or our partner chooses to advance. We see also gains in productivity. Let's just take an example in designing molecules.
In designing first-in-class molecules, we are now synthesizing 80%-90% fewer compounds across our portfolio relative to industry benchmarks. In the clinic, ClinAgent can screen thousands of trial sites in minutes to help us find sites that actually see the patients we're trying to reach. We're seeing enrollment run about 30%-60% faster than industry benchmarks. We are advancing all of this work from a stronger financial position. We just completed our oversubscribed $200 million financing in October, bringing in leading institutional investors, and now expect our cash runway to extend into 2029. At the same time, as previously communicated, we have lowered our 2026 cash operating expense guidance from $390 million to $375 million. Then now looking ahead for 2027, we expect that figure to come down even further to under $360 million.
Before we go into a deep dive of the clinical programs, let me take you behind the scenes of a couple of our partnership programs and some of the updates to date. Let's start with the Sanofi announcement. We set out to design one oral small molecule that could inhibit two targets involved in inflammatory disease. That's a difficult chemistry problem. Not only is it first in class, but a change that improves activity in one target could come at the expense of the other, and you still have to preserve the properties that actually allow this to be a chronically dosed oral compound. For patients who may need this treatment for years, an oral option could make a meaningful difference in daily life. That's the kind of first-in-class design challenge we want to take on.
Sanofi brought deep expertise in immunology and drug discovery, and our team used our AI platform to design the molecules, test them in the lab, and use what we learned to refine that next design. Sanofi has now optioned the candidate and will lead and fund its further development, with phase I expected to begin in 2027. This is the first development candidate Sanofi has optioned from our collaboration and our sixth milestone across five programs together. That track record is what gives us confidence in the repeatability of our work. The option triggered a $10 million payment, bringing total upfront and milestone payments from Sanofi to be $144 million. Under the collaboration, each program has up to $343 million in potential milestone payments, plus double-digit royalties on net sales.
Now, while with Sanofi, the challenge was to design one small molecule across two targets, with Roche, we started with a different problem. We knew what cancer pathway we wanted to reach, but it had been long considered undruggable. Could our maps reveal a way in? Roche highlighted this work at its September investor day this year. Together, we mapped how cells responded when we altered individual genes and then exposed them to compounds. It's this gene-compound relationship that helped our biology engine to identify a new mechanism for acting on this pathway. We then advanced the most promising compounds and confirmed in vivo that they acted on that intended pathway. Much more work to come on here. In the neuroscience space, instead of knowing whether there was an undruggable pathway, the question was slightly different.
The question was, can our maps of biology find novel causal targets that were previously unknown? This work is a great example of what deep collaboration looks like for us. We generated high-dimensional proprietary maps of biology from human neurons to uncover genes with unexpected links to disease biology. Our teams then worked side by side to prioritize the most compelling targets and then tested them experimentally, building that body of evidence around which ones are worth advancing. Genentech has now optioned the first target from that work, and small molecule discovery is underway that we're working on together. Importantly, the value of the collaboration doesn't stop with a single target. We are continuing to work in advance using the same reusable maps to generate and test additional hypotheses, creating the potential for multiple programs to emerge from that one shared dataset.
Now, what ties all these examples together is how we're using one platform across different programs and different disease areas. With Roche Genentech, we uncovered new biology that led to a novel target and more coming in neuroscience. With Roche Genentech in oncology, we found a new way to act on a pathway long considered undruggable. With Sanofi, we designed one oral molecule to act on two targets in immunology. In our own pipeline with REC-4881 and REC-1245 in rare disease and in oncology, we're beginning to see those biological insights translate into activity in patients. Now, before I turn to the REC-4881 data, I also want to share an important board update. Today, we announced that our board unanimously appointed Fred Hassan as chair.
Fred has repeatedly built, scaled, and transformed some of the most important companies in our industry, including as Chairman and CEO of Schering-Plough and Pharmacia. He also brings a wealth of board perspective and experience from companies including Amgen, BridgeBio, and Prometheus. What matters to me is the perspective Fred brings at this stage of Recursion. He understands firsthand what it takes to transform companies, to move companies from clinical proof through approval and launch, while building enduring businesses around them. He also shares our conviction that data and AI are creating a new blueprint from drug discovery and development. Fred will serve as a non-executive chair, and I'm very excited to work with him as we enter the next chapter. I'm also grateful to Rob Hershberg for his commitment to Recursion and for the perspective he has brought on from many years as physician, scientist, and biotech CEO.
Rob will remain on the board, and we will continue to benefit from his insights. Now, let's turn to REC-4881, our investigational oral MEK1/2 inhibitor for FAP. Yesterday in Denver, Dr. Lisa Boardman presented the updated TUPELO results in the presidential plenary at CGA-IGC. What makes this meeting particularly relevant to FAP is who's in the room. It brings together the genetic counselors who help families understand their risk, the specialized GI physicians and surgeons who take care of them, and the researchers working on new treatments. I'll share the highlights here. This update gives a broader and more complete picture of the program. It includes additional patients, where we have now expanded eligibility to adults age 18 and older. Importantly, we continue to see the depth and durability of response across and throughout the GI tract.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
